This article explores the long-standing controversy over the proper role for the courts in resolving business disputes affecting generic drug competition. The disputes are grounded in some interesting, albeit perplexing, discussions of basic issues involving jurisdiction.
Mark E. Waddell is a partner and co-chair of the patent litigation practice group in the New York office of Loeb & Loeb LLP and can be reached at firstname.lastname@example.org.
This article was first printed in the June 2008 edition of The Metropolitan Corporate Counsel. Permission for article reprint has been granted.